E Therapeutics (ETX)

 

ETX Share PerformanceMore

52 week high27.2500 20/01/16
52 week low7.0000 22/12/16
52 week change -18.7500 (-69.12%)
4 week volume2,446,968 23/12/16

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Holding(s) in Company

RNS Number: 0203U e-Therapeutics plc 12 January 2017 For filings with the FCA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii e-Therapeutics plc 2 Reason for the notification (please tick t...

e-Therapeutics appoints CEO

e-Therapeutics has appointed Dr. Raymond Barlow as chief executive. He will take up the role on or before 1 May, at which...

Appointment of CEO

Notification of any change to a company’s board e.g. appointments/resignations/changes to important functions or executive responsibilities of a director

Director Deals - e-Therapeutics PLC (ETX)

Prof Trevor Jones, Non Executive Director, received in lieu of fees/salary 36,917 shares in the company on the 3rd January...

Director/PDMR Shareholding

Grant of share options and Directors' dealings

RNS Number: 9836P e-Therapeutics plc 23 November 2016 23 November 2016 e-Therapeutics plc ('e-Therapeutics' or 'the Company') Grant of share options and Directors' dealings Oxford and Newcastle, UK, 23 November 2016 - e-Therapeutics plc (AIM: ETX) the drug discovery company, announces that on 23 November 2016 the Company granted options over a total o...

Director Deals - e-Therapeutics PLC (ETX)

Prof Trevor Jones, Non Executive Director, bought 41,204 shares in the company on the 5th October 2016 at a price of 11.33p...

Directors' Dealings and Issue of Equity

RNS Number: 8817L e-Therapeutics plc 06 October 2016 e-Therapeutics plc ('e-Therapeutics' or 'the Company') Directors' Dealings and Issue of Equity Oxford and Newcastle, UK, 6 October 2016 - e-Therapeutics plc (AIM: ETX) the drug discovery company, announces that o n 5 October 2016 Professor Trevor Jones (Non-Executive Director) subscribed for a total of 41,20...

Fundamental DataMore

EPS-3.34
Dividend yield0 %

Equity Research (ETX)

edison investment research
e-Therapeutics plc
16/01/2017
e-Therapeutics (ETX) has appointed a new CEO, Dr Raymond Barlow, who will join the company by 1 May 2017. He brings significant R&D and business development experience, which will be invaluable...
edison investment research
e-Therapeutics plc.
20/09/2016
e-Therapeutics (ETX) is focused on driving value in its discovery platform. Costs will be reduced as the 17 product candidates in discovery as of July 2016 have been cut to a core five. Cash of £19....
edison investment research
e-Therapeutics plc.
19/05/2016
e-Therapeutics’ strategy has evolved, shifting from investment into its proprietary discovery platform to commercialisation of its 12 preclinical assets and the platform itself. Out-licensing and...

Latest discussion posts More

  • Results

    RNS available at company's website. although seems to be missing in III ...
    22-Mar-2016
    nk1999
  • Re: Good news but why?

    RNS out today afternoon. Good operational progress. Not sure if that warrants a steep rise in SP as seen over the last few days, including a further 15% today. But I ...
    26-Feb-2015
    nk1999
  • Re: Good news but why?

    Clearly somebody knows something we don't. Would that be called insider trading I wonder.
    26-Feb-2015
    Actinidia

Users' HoldingsMore

Users who hold E Therapeutics also hold..
LLOYDS GRP.32%
RENEURON28%
ROCKHOPPER24%
ANGLE20%
RANGE RES.20%

Codes & Symbols

ISINGB00B2823H99
SymbolsETX, LSE:ETX, ETX.L, ETX:LN, LON:ETX, XLON:ETX